UniProtKB/Swiss-Prot P60484: Variant p.Val191Ala

Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
Gene: PTEN
Feedback?

Variant information Variant position:

191 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant:

US The variants are classified into three categories: LP/P, LB/B and US.

LP/P: likely pathogenic or pathogenic.
LB/B: likely benign or benign.
US: uncertain significance

Residue change:

From Valine (V) to Alanine (A) at position 191 (V191A, p.Val191Ala). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties:

Change from medium size and hydrophobic (V) to small size and hydrophobic (A) The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score:

0 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:

Lowest score: -4 (low probability of substitution).
Highest score: 11 (high probability of substitution).

More information can be found on the following page
Variant description:

In endometrial hyperplasia. Any additional useful information about the variant.

Sequence information Variant position:

191 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length:

403 The length of the canonical sequence.
Location on the sequence:

QRRYVYYYSYLLKNHLDYRP V ALLFHKMMFETIPMFSGGTC The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation:

The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         QRRYVYYYSYLLKNHLDYRPVALLF-------------------------HKMMF--------------------------------------------------ETIPM------------------FSGGT-------------------------------------------------------------------------------------------------------------------------------------------------------C

                              QRRYVYYYSYLLKNHLDYRPVALLF----------------

Mouse                         QRRYVYYYSYLLKNHLDYRPVALLF----------------

Rat                           QRRYVYYYSYLLKNHLDYRPVALLF----------------

Xenopus laevis                QRRYVYYYSYLLKNSLEYRPVPLLF----------------

Caenorhabditis elegans        QRRYIYYYHKLRERELNYLPLRMQLIGVYVERPPKTWGGGS

Slime mold                    QIRYVGYFGRSIRESIKYVPRNVTL----------------

Fission yeast                 QIRYVYYIE-ILKQFPNY------L----------------

Sequence annotation in neighborhood:

The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:

Type: the type of sequence feature.
Positions: endpoints of the sequence feature.
Description: contains additional information about the feature.

Type	Positions	Description
Chain	2 – 403	Phosphatidylinositol 3,4,5-trisphosphate 3-phosphatase and dual-specificity protein phosphatase PTEN
Domain	190 – 350	C2 tensin-type
Alternative sequence	191 – 403	Missing. In isoform 3.
Mutagenesis	171 – 171	Q -> AE. 75% reduction in phosphatase activity towards PtdIns(3,4,5)P3.

Literature citations
Mutation of the PTEN tumor suppressor gene in endometrial hyperplasias.
Maxwell G.L.; Risinger J.I.; Gumbs C.; Shaw H.; Bentley R.C.; Barrett J.C.; Berchuck A.; Futreal P.A.;
Cancer Res. 58:2500-2503(1998)
Cited for: VARIANTS ENDOMETRIAL HYPERPLASIA ARG-36; LEU-130; CYS-173; ALA-191 AND ILE-348;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.